High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
NCT ID: NCT00669812
Last Updated: 2013-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
60 participants
INTERVENTIONAL
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying high-dose chemotherapy given together with peripheral blood stem cell transplant in treating patients with intestinal T-cell lymphoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* To assess the efficacy and toxicity of intensive high-dose chemotherapy (alternating I'VE regimen and intermediate-dose methotrexate) followed by autologous peripheral blood stem cell transplantation for treatment of patients with intestinal T-cell lymphoma.
Secondary
* To assess the toxicity of the regimen in a large population of these patients.
* To provide a coordinated approach to the treatment of these patients.
* To register patients unfit for the protocol chemotherapy into the pathological part of the study.
OUTLINE: This is a multicenter study
* Chemotherapy: Patients receive CHOP chemotherapy comprising cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5.
After recovering from CHOP chemotherapy, patients receive I'VE chemotherapy comprising epirubicin hydrochloride IV on day 1 and etoposide IV over 2 hours and ifosfamide IV continuously on days 21-23. Patients also receive methotrexate IV over 24 hours on day 21. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
* Consolidation therapy: On day 77, stem cells are collected from patients if the marrow is clear of disease. After completion of chemotherapy, patients in complete remission receive carmustine IV on day 105, cytarabine IV and etoposide IV on days 106-109, and melphalan IV on day 110. These patients undergo autologous peripheral blood stem cell transplantation on day 112.
Prior to study treatment, patients undergo a biopsy of the gut to confirm diagnosis and a blood sample is taken. Both blood and tissue samples may be used for further studies.
After recovery from treatment, patients are followed monthly for 4 months, then bimonthly for 1 year, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carmustine
cyclophosphamide
cytarabine
doxorubicin hydrochloride
epirubicin hydrochloride
etoposide
ifosfamide
melphalan
methotrexate
prednisolone
vincristine sulfate
autologous hematopoietic stem cell transplantation
biopsy
peripheral blood stem cell transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly confirmed diagnosis of intestinal T-cell lymphoma/ enteropathy-type T-cell lymphoma according to the following WHO classifications:
* Usual phenotype CD3-, CD7-positive; CD5-, CD4-, CD8-negative; or CD30-positive
* Complete surgical resection allowed
PATIENT CHARACTERISTICS:
* Unsupported neutrophils ≥ 1,500/mm\^3 unless attributed to lymphomatous bone marrow infiltration
* Unsupported platelets ≥ 100,000/mm\^3 unless attributed to lymphomatous bone marrow infiltration
* Creatinine clearance ≥ 50 mL/min
* Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
* Bilirubin ≤ 2.5 times ULN
* Left ventricular ejection fraction ≥ 50%
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment
* Patients with any serious concomitant medical or psychiatric condition that would preclude them tolerating the planned treatment should be entered into the registration study only
* No known hepatitis B, hepatitis C, or HIV positivity
* No active uncontrolled cardiovascular disease
* No abnormal EKG if there is a previous history of cardiac problems
* No other severe impairment of cardiac function
* No active malignancy within the past 5 years except cervical intraepithelial neoplasia or localized skin cancer
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* Prior diagnostic or emergency surgical procedures allowed
* More than 5 years since prior treatment for malignancy
* No prior chemotherapy or radiotherapy for treatment of lymphoma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research UK
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Lennard
Role: PRINCIPAL_INVESTIGATOR
Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Newcastle upon Tyne, England, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne Lennard
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Phillips EH, Lannon MM, Lopes A, Chadwick H, Jones G, Sieniawski M, Davies A, Wood K, Clifton-Hadley L, Smith P, Lawrie A, Chadwick N, Lennard AL. High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study. Bone Marrow Transplant. 2019 Mar;54(3):465-468. doi: 10.1038/s41409-018-0294-2. Epub 2018 Aug 13. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRUK-2005-003906-27
Identifier Type: -
Identifier Source: secondary_id
CRUK-BRD/05/93
Identifier Type: -
Identifier Source: secondary_id
CDR0000593564
Identifier Type: -
Identifier Source: org_study_id